Research programme: anti-muscarinic and inhaled corticosteroid combination therapeutic - Almirall

Drug Profile

Research programme: anti-muscarinic and inhaled corticosteroid combination therapeutic - Almirall

Alternative Names: AB/ICS; Aclidinium bromide/ICS; LAS 40369

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Laboratorios Almirall
  • Class
  • Mechanism of Action Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Europe (Inhalation)
  • 02 Aug 2007 Preclinical trials in Chronic obstructive pulmonary disease in Europe (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top